{"id":"NCT00809471","sponsor":"VIVUS LLC","briefTitle":"Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in the Treatment of Erectile Dysfunction in Diabetic Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2008-12-17","resultsPosted":"2012-06-28","lastUpdate":"2012-08-17"},"enrollment":390,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Erectile Dysfunction"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"avanafil","otherNames":["TA-1790","Stendra"]},{"type":"DRUG","name":"avanafil","otherNames":["TA-1790","Stendra"]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"avanafil 100 mg","type":"EXPERIMENTAL"},{"label":"avanafil 200 mg","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to compare the safety and efficacy of 2 doses of avanafil to placebo in diabetic men with mild to severe erectile dysfunction.","primaryOutcome":{"measure":"Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse","timeFrame":"Baseline, 12-weeks","effectByArm":[{"arm":"Placebo","deltaMin":13.6,"sd":2.77},{"arm":"Avanafil 100 mg","deltaMin":28.7,"sd":2.78},{"arm":"Avanafil 200 mg","deltaMin":34,"sd":2.76}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":30},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":["22857780"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":130},"commonTop":["headache","nasopharyngitis","flushing","back pain","sinus congestion"]}}